Myopia has become a global public health problem
.
In China, the number of myopic patients has exceeded 600 million, and it is mainly teenagers
.
According to data released by the National Health Commission in July 2021, the overall myopia rate of children and adolescents in China in 2020 was 52.
7%, of which 14.
3% were 6-year-old children, 35.
6% were primary school students, 71.
1% were junior high school students, and 80.
5%
were high school students.
The "Implementation Plan for Comprehensive Prevention and Control of Myopia in Children and Adolescents" previously issued by eight departments in China proposed that the future prevention and control goals are to control the myopia rate of 6-year-old children at about 3%, the myopia rate of primary school students to less than 38%, the myopia rate of junior high school students to less than 60%, and the myopia rate of high school students to below
70%.
As myopia has attracted more and more attention from the society, the industry believes that it is timely
for the myopia eye drug market to seize the land.
At present, targeting a considerable market, many pharmaceutical companies have also entered the market
.
News on December 15, Xingqi Eye Medicine announced the completion of the 1-year phase III clinical trial summary report
of atropine sulfate eye drops.
The report pointed out that the atropine sulfate eye drops of Xingqi Eye Medicine have good safety and good patient compliance
.
Atropine is an anticholinergic that can be used to slow the progression of myopia and axial lengthening
in children with low to moderate myopia.
In addition to Xingqi eye medicine, Aier Ophthalmology, He's Ophthalmology, etc.
also have different specifications of atropine eye drops have been approved for preparation registration by medical institutions
.
Among them, Zhaoke Ophthalmology introduced the rights
to develop and commercialize low-concentration atropine sulfate NVK002 developed by Nevakar in the United States in China, South Korea and some Southeast Asian countries and regions.
In October this year, Zhaoke Ophthalmology announced the positive results of a phase III CHAMP study of two doses of NVK002 for the deepening of myopia in children, and Zhaoke Ophthalmology is currently conducting two phase III clinical trials
in parallel for NVK002 in China.
The company also said that after NVK002 is approved by the FDA, the company plans to submit new drug applications
in China based on the results of clinically relevant phase III clinical trials in China and data from small and phase III CHAMP studies.
In June 2021, Ocomvision Biologics also announced the official launch of a low-concentration atropine OT-101 real-world study
.
According to reports, OT-101 is a low-concentration atropine 0.
01% eye drop developed by the company to delay or slow down the progression
of myopia in children and adolescents.
Ocomvision Biologics is currently conducting Phase III international multi-center clinical trials
in China, the United States and the United Kingdom.
It is worth mentioning that in November this year, the State Food and Drug Administration issued the draft of the "Drug Online Sales Prohibition List", and the preparations of medical institutions were clearly listed in the list of drugs prohibited from online sales by policies and regulations, which the industry believes means that atropine cannot be sold online, and related companies may lose part of the market
.
In July this year, Shenyang Xingqi Eye Hospital, a wholly-owned subsidiary of Xingqi Eye Medicine, also issued a notice that the hospital's Internet hospital suspended the prescription of 0.
01% atropine sulfate eye drops in the hospital, which can only be purchased
in physical hospitals.
In addition, Hengrui Pharmaceutical is also targeting the myopia drug market, and the company announced in June 2021 that it will launch a phase III clinical trial
of HR19034 eye drops for the prevention and control of myopia progression in children.
It is reported that HR19034 is a new drug that acts on the sclera, choroid, retina related receptors, the company said that no similar products at home and abroad have been approved for marketing
.
With the smooth progress of phase III clinical trials of many myopia drugs, it is expected that these drugs will be launched as soon as possible, benefit the majority of myopia patients, and complete the indicators
proposed in the Implementation Plan for Comprehensive Prevention and Control of Myopia in Children and Adolescents.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
